AUG 19, 2026 · PHASE 1 TRIAL
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
ClinicalTrials.gov
Phase 1 safety and tolerability study in a small population (n=24) with surrogate mechanistic endpoints; no efficacy data reported and recruitment not yet started.
Reported
Planned sample size24
Study phasePhase 1
Duration of active intervention28 days